Robert A. Hauser, MD, MBA

Panelists discuss how the recently FDA-approved SPN-830 apomorphine infusion pump demonstrated significant efficacy in reducing off time and improving motor function in the INFUS-ON study, with physicians expressing optimistic views about both the US and European clinical trial results.

Panelists discuss how continuous subcutaneous apomorphine infusion (CSAI) demonstrates favorable pharmacokinetics compared with other formulations, with the TOLEDO study and its extension showing significant reductions in off time and improvements in motor function with manageable safety profiles.

Panelists discuss how early recognition of dyskinesia symptoms, ongoing patient-clinician communication, and individualized treatment strategies are key to effectively managing Parkinson disease and improving patients’ quality of life.

Panelists discuss how adjunctive therapies play a crucial role in managing Parkinson disease symptoms, with a particular focus on apomorphine’s unique position in the treatment landscape due to its distinct dopamine receptor binding profile compared with other dopaminergic agents.

Panelists discuss how physicians typically consider advanced Parkinson disease treatments when conventional therapies fail to adequately control motor fluctuations, highlighting challenges such as adverse effects, device-related complications, and patient selection criteria.

Panelists discuss how physicians approach conversations about off time with patients with Parkinson disease, balancing clinical assessment with patient education and shared decision-making.

Panelists discuss how understanding and communication of off episodes for patients with Parkinson disease varies widely in clinical settings, often hindering optimal symptom management.

Panelists discuss how early recognition of dyskinesia symptoms, ongoing patient-clinician communication, and individualized treatment strategies are key to effectively managing Parkinson disease and improving patients’ quality of life.

Panelists discuss how treatment changes in Parkinson disease are necessitated by disease progression, diminishing medication effectiveness, and emerging motor complications, examining a physician’s systematic approach to treatment adjustments and the range of available options for managing off fluctuations.

Panelists discuss how off fluctuations in Parkinson disease become increasingly prevalent as the disease progresses, significantly impacting patient quality of life through reduced mobility, independence, and overall well-being.

Panelists discuss how recent advancements in Parkinson’s disease treatments and a patient-centered approach to care are essential in managing dyskinesia while improving overall symptom control.

Panelists discuss how recent advancements in Parkinson’s disease treatments and a patient-centered approach to care are essential in managing dyskinesia while improving overall symptom control.

The panelists provided clinical insight on the utilization of IPX203, its potential benefits and clinical implications, as well as the practicalities of transitioning patients from other therapies.

The panelists discussed the safety profile of IPX203, considering challenges with transitioning, dosing strategies, and monitoring and adjusting patients’ individual dosage.

Dr. Hauser and Dr. Fernandez provided insight on the body of supportive evidence for IPX203, the notable takeaways from RISE-PD, and the long-term benefits observed from treated patients.

IPX203 combines immediate and extended-release levodopa, utilizing advanced delivery technology to optimize absorption and prolong therapeutic effects in patients with Parkinson disease.

In this opening segment, Hauser and Fernandez discussed the FDA approval of IPX203, a new long-acting levodopa formulation for Parkinson disease, highlighting its significance in improving treatment options and patient compliance.

Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.

Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.

Robert Hauser, MD, MBA, discussed unmet needs and future consideration in Parkinson disease.

Robert Hauser, MD, MBA, talks about amantadine extended release for management of dyskinesia and OFF episodes.

Robert Hauser, MD, MBA, shares his expertise in the treatment of OFF time in Parkinson disease.

Robert Hauser, MD, MBA, reviews the predictability of dyskinesia and OFF episodes in Parkinson disease.

Robert Hauser, MD, MBA, discusses how the patient experience is defined in Parkinson disease.

The expert panel reviews unmet needs in treatment and management of dyskinesia and shares advice for physicians treating patients with Parkinson disease.

Drs Fernando Pagan, Robert A. Hauser, and Daniel Kremens highlight existing and emerging surgical and pharmacological options for treatment of dyskinesia in Parkinson disease.

The expert neurology panel shares their clinical experience with different formulations of amantadine in management of dyskinesia in patients with Parkinson disease.

The expert panel reviews the safety profile of amantadine DR/ER and who may be an ideal patient for its use in patients with Parkinson disease experiencing dyskinesia.

The expert neurology panel discusses clinical trial data of amantadine-DR/ER in treatment of dyskinesia and OFF episodes in Parkinson disease.

Drs William G. Ondo and Rajesh Pahwa analyze the pharmacokinetics of different formulations of amantadine for treatment of dyskinesia in Parkinson disease.